Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 414 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Other Neurological Disorders Clear all
Completed Phase 1 Interventional

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

NCT00020150
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
O6-benzylguanine, temozolomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 28, 2026, 5:11 AM EDT
Terminated Not applicable Interventional Results available

Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia

NCT01595503
View directory record Official record
Conditions
Schizophrenia
Interventions
rTMS with fMRI-based targeting, rTMS with landmark-based targeting
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 28, 2026, 5:11 AM EDT
Completed No phase listed Observational

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

NCT01158183
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BAY86-5046_Interferon-beta-1b
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
27
States / cities
Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2010 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

New Drugs in the Treatment of Mood Disorders

NCT00001482
View directory record Official record
Conditions
Anxiety Disorder, Mood Disorder, Psychotic Disorder
Interventions
Lamotrigine (Lamictal® (Registered Trademark), Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 5:11 AM EDT
Completed No phase listed Observational

Prevalence of Visual Dysfunction in Neurological Disorders

NCT04836715
View directory record Official record
Conditions
Parkinson Disease, Other Neurological Disorders, Healthy
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
92 participants
Timeline
2021 – 2023
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 28, 2026, 5:11 AM EDT
Recruiting Early Phase 1 Interventional

Aprepitant for the Treatment of CLIFAHDD

NCT07845825
View directory record Official record
Conditions
CLIFAHDD, Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay, NALCN Channelopathy, Ataxia - Other, Neurodevelopmental Disorder (Diagnosis)
Interventions
Aprepitant Powder for Oral Suspension
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
6 Months and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 5:11 AM EDT
Completed No phase listed Observational

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

NCT02109770
View directory record Official record
Conditions
Microdeletion Syndromes, Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
Not listed
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
San Carlos, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 28, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

NCT00548327
View directory record Official record
Conditions
Schizophrenia, Memory Disorders, Cognition Disorders
Interventions
Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing, Placebo
Drug · Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 28, 2026, 5:11 AM EDT
Completed No phase listed Observational

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

NCT01442194
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
other disease-modifying therapy, Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
3,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
208
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Not applicable Interventional

More Individualized Care: Assessment and Recovery Through Engagement

NCT05122676
View directory record Official record
Conditions
Depression, Anxiety, Opioid-Related Disorders, Pain, Chronic
Interventions
More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 28, 2026, 5:11 AM EDT
Terminated Early Phase 1 Interventional

11C Topotecan PET Imaging

NCT00253461
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
computed tomography, positron emission tomography, 11C topotecan, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 28, 2026, 5:11 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization and Natural History of Williams Syndrome and Other Chromosome 7q11.23 Variants

NCT06930417
View directory record Official record
Conditions
Williams Beuren Syndrome, Williams Syndrome, Williams Beuren Region Duplication, Dup7
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2045
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

NCT00030108
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Leukemia, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ixabepilone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00477672
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103), Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 28, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2009 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Legacy Intervention Family Enactment (LIFE)

NCT02007564
View directory record Official record
Conditions
Pain, Retention Disorders, Cognitive, Other Chronic Illness, Palliative Care
Interventions
LIFE Intervention
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease

NCT03582137
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS

NCT02549859
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Deep Brain Stimulation (DBS) at 60 Hz, Deep Brain Stimulation (DBS) at 130 Hz, Deep Brain Stimulation (DBS) Off (Sham)
Device
Lead sponsor
University of Chicago
Other
Eligibility
45 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 28, 2026, 5:11 AM EDT
Terminated Not applicable Interventional Results available

Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations

NCT05319080
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Columbia University
Other
Eligibility
22 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MEK162 for Children With Low-Grade Gliomas

NCT02285439
View directory record Official record
Conditions
Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions
MEK162
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NCT02960230
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
K27M peptide, Nivolumab
Biological · Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 28, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Parkinsonism in Spinocerebellar Ataxia Type 6

NCT01934998
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 6
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 28, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Psychosis and Agitation in Alzheimer's Disease

NCT02129348
View directory record Official record
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Lithium, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Miami, Florida • Belmont, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 28, 2026, 5:11 AM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 28, 2026, 5:11 AM EDT